EWTX — Edgewise Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1710072 ·
Last close
$42.04
Market Cap
$4.60B
52W High
$48.78
52W Low
$19.76
ADV30
1,601,037
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -46,143,000 | 1,166,151,000 | 1,780,020,000 | 68,680,000 | 147,352,000 |
| Jun 2026 | 0 | — | -61,943,000 | -57,327,000 | 479,688,000 | 72,319,000 | 31,611,000 |
| Mar 2026 | 0 | — | -54,115,000 | -49,013,000 | 518,522,000 | 33,211,000 | 25,319,000 |
| Dec 2025 | 0 | — | -55,979,000 | -50,216,000 | 552,603,000 | 61,148,000 | 30,346,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-201,895,000
Investing CF
$190,360,000
Financing CF
$34,212,000
CapEx
$-382,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$8.19
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$513,440,000
Inventory
—
Receivables
—
ST Investments
$1,675,213,000
EBIT TTM
$-218,180,000
Pretax Income TTM
$1,164,928,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -191,406,000 | -167,795,000 | 552,603,000 | 30,346,000 | 522,257,000 | -143,816,000 |
| Dec 2024 | 0 | -158,832,000 | -133,813,000 | 486,817,000 | 27,601,000 | 459,216,000 | -109,028,000 |
| Dec 2023 | 0 | -114,357,000 | -100,163,000 | 340,035,000 | 21,205,000 | 318,830,000 | -91,948,000 |
| Dec 2022 | 0 | -71,658,000 | -67,640,000 | 367,101,000 | 20,385,000 | 346,716,000 | -52,635,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-197,222,000
OpCashFlow TTM
—
Assets (Latest)
$479,688,000
Forward EPS
$-1.75
Max Pain — expiry 2026-12-18
max pain strike: $40.00 · spot: $41.37 · call oi: 7,470 · put oi: 932Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | $4.64B | $95.11 | — |
| GIKLY | Grifols SA | $4.69B | $5.55 | — |
| IONS | IONIS PHARMACEUTICALS INC | $4.49B | $26.96 | — |
| COGT | Cogent Biosciences, Inc. | $4.85B | $27.85 | — |
| ERAS | Erasca, Inc. | $4.87B | $13.89 | — |
News headlines (Yahoo Finance, 1h cache)
/C O R R E C T I O N - Edgewise Therapeutics/
2026-11-09 16:41 · Yahoo
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
2026-11-09 13:00 · Yahoo
Why Edgewise Therapeutics Stock Is In Focus After Phase 3 Filing For Heart Drug
2026-11-07 13:16 · Yahoo
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
2026-11-05 13:00 · Yahoo
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
2026-11-04 21:01 · Yahoo
Servier’s $1.55bn muscular dystrophy drug fails Phase II BMD trial
2026-11-04 12:35 · Yahoo
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
2026-11-02 13:00 · Yahoo
Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says
2026-10-27 15:53 · Yahoo
Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
2026-10-15 02:11 · Yahoo
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
2026-10-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.